Reviewer’s report

Title: Gemcitabine induced cardiomyopathy: A case report and review of the literature

Version: 1 Date: 11 March 2014

Reviewer: Mario Camarda

Which of the following best describes what type of case report this is?: Unreported or unusual side effects or adverse interactions involving medications

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: No

Is this case worth reporting?: Yes

Is the case report persuasive?: Yes

Does the case report have explanatory value?: Yes

Does the case report have diagnostic value?: Yes

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

Comments to authors:

The case report is very interesting and it shows a little-known aspect of the use of gemcitabine. The relationship between the use of the drug and the appearance of such a severe depression of systolic function seems clear. Functional recovery of myocardial vitality after suspension of the drug is the proof. Moreover I appreciated the extensive work done by the authors of review of the Literature about cases of cardiotoxicity associated with the use of the drug. It would be very interesting to know the diameter of the left ventricle (not only EF) before and after discontinuation of therapy. But this does not change my positive opinion of the manuscript.

Quality of written English: Acceptable
Declaration of competing interests:

I declare that I have no competing interests.